Biocon Group, along with German subsidiary AxiCorp, has posted a total income of Rs 1098 crores, up by 50% YoY for half-year ended on September 30, 2009. Earnings before interest, taxes, depreciation and amortization (EBITDA) has peaked to Rs 236 crores registering an year-on-year growth at 40%.

Biocon believes its oral insulin pill IN-105 has the potential to become a multibillion dollar blockbuster

India's leading biotherapeutics firm Biocon Ltd has entered into pact with Amylin on diabetes treatment.

Mylan will have commercialization rights of Biocon’s products in US, Canada, Japan, Australia, New Zealand and EU.